Results from the pivotal IDE study ASPIRE revealed that PearlMatrix achieved greater clinical success and faster time-to-fusion at 24 months compared to local autograft. The study, known for its rigorous design, included over twice the number of patients. This demonstrates the superiority of PearlMatrix in terms of both clinical outcomes and efficiency in achieving fusion within the specified timeframe.